enow.com Web Search

Search results

1. Results from the WOW.Com Content Network

2. Bcr-Abl tyrosine-kinase inhibitor - Wikipedia

   en.wikipedia.org/wiki/Bcr-Abl_tyrosine-kinase...

   Bcr-Abl tyrosine-kinase inhibitors ( TKI) are the first-line therapy for most patients with chronic myelogenous leukemia (CML). More than 90% of CML cases are caused by a chromosomal abnormality that results in the formation of a so-called Philadelphia chromosome. This abnormality was discovered by Peter Nowell in 1960 [1] and is a consequence ...

3. Philadelphia chromosome - Wikipedia

   en.wikipedia.org/wiki/Philadelphia_chromosome

   The Philadelphia chromosome or Philadelphia translocation ( Ph) is a specific genetic abnormality in chromosome 22 of leukemia cancer cells (particularly chronic myeloid leukemia (CML) cells). This chromosome is defective and unusually short because of reciprocal translocation, t (9;22) (q34;q11), of genetic material between chromosome 9 and ...

4. Fox Chase Cancer Center - Wikipedia

   en.wikipedia.org/wiki/Fox_Chase_Cancer_Center

   Fox Chase Cancer Center. / 40.071848; -75.090206. Fox Chase Cancer Center is a National Cancer Institute -designated Comprehensive Cancer Center research facility and hospital located in the Fox Chase section of Philadelphia, Pennsylvania, United States. The main facilities of the center are located on property adjoining Burholme Park.

5. Chronic myelogenous leukemia - Wikipedia

   en.wikipedia.org/wiki/Chronic_myelogenous_leukemia

   Deaths. 32,200 (2015) [2] Chronic myelogenous leukemia ( CML ), also known as chronic myeloid leukemia, is a cancer of the white blood cells. It is a form of leukemia characterized by the increased and unregulated growth of myeloid cells in the bone marrow and the accumulation of these cells in the blood. CML is a clonal bone marrow stem cell ...

6. Novartis leukemia drug more effective than older treatments ...

   www.aol.com/news/novartis-leukemia-drug-more...

   Swiss drugmaker Novartis said patients with a type of leukemia who took its Scemblix had a significantly better response and a lower dropout rate than those who received current standard-of-care ...

7. Imatinib - Wikipedia

   en.wikipedia.org/wiki/Imatinib

   The U.S. Food and Drug Administration (FDA) has approved imatinib as first-line treatment for Philadelphia chromosome-positive CML, both in adults and children. The drug is approved in multiple contexts of Philadelphia chromosome-positive CML, including after stem cell transplant, in blast crisis, and newly diagnosed. [11]